BoffaDJ, RosenJE, MallinK, Using the National Cancer Database for outcomes research: a review. JAMA Oncol 2017;3:1722–1728.2824119810.1001/jamaoncol.2016.6905)| false
Tchelebi LT, Shin B, Wang M, et al. Impact of radiation therapy facility volume on survival in patients with cancer. Cancer, in press.
4.
ZaorskyNG, ZhangY, WalterV, et al.Clinical trial accrual at initial course of therapy for cancer and its impact on survival. J Natl Compr Canc Netw2019;17:1309–1316.
ZaorskyNG, ZhangY, WalterV, Clinical trial accrual at initial course of therapy for cancer and its impact on survival. J Natl Compr Canc Netw 2019;17:1309–1316.3169398610.6004/jnccn.2019.7321)| false
HaslamA, PrasadV.Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open2019;2:e192535.
HaslamA, PrasadV.Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2019;2:e192535.10.1001/jamanetworkopen.2019.253531050774)| false
MarquartJ, ChenEY, PrasadV.Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol2018;4:1093–1098.
MarquartJ, ChenEY, PrasadV.Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol 2018;4:1093–1098.2971018010.1001/jamaoncol.2018.1660)| false
TchelebiL, BatchelderE, WangM, et al. Radiotherapy and receptor tyrosine kinase inhibition for solid cancers (ROCKIT): a meta-analysis of 13 studies JNCI Cancer Spectrum 2021:pkab050.
TchelebiL, BatchelderE, WangM, Radiotherapy and receptor tyrosine kinase inhibition for solid cancers (ROCKIT): a meta-analysis of 13 studies JNCI Cancer Spectrum 2021:pkab050.10.1093/jncics/pkab050)| false
